<SEC-DOCUMENT>0001178913-25-001274.txt : 20250410
<SEC-HEADER>0001178913-25-001274.hdr.sgml : 20250410
<ACCEPTANCE-DATETIME>20250410172551
ACCESSION NUMBER:		0001178913-25-001274
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250410
DATE AS OF CHANGE:		20250410

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-86953
		FILM NUMBER:		25829308

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SPHERA FUNDS MANAGEMENT LTD.
		CENTRAL INDEX KEY:			0001496201
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		4 ITZHAK SADE BUILDING A
		STREET 2:		29TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6777520
		BUSINESS PHONE:		972-3-6845535

	MAIL ADDRESS:	
		STREET 1:		4 ITZHAK SADE BUILDING A
		STREET 2:		29TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6777520
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001178913-24-002709</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001496201</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>1</amendmentNo>
<securitiesClassTitle>American Depository Shares, each representing twenty (20) ordinary shares, no par value</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001534248</issuerCik>
<issuerName>Chemomab Therapeutics Ltd.</issuerName>
<issuerCusip>16385C104</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>Kiryat Atidim, Building 7</com:street1>
<com:city>Tel Aviv</com:city>
<com:stateOrCountry>L3</com:stateOrCountry>
<com:zipCode>6158002</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Sphera Funds Management Ltd.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>900428</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>900428</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>900428</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>4.78</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>Percentage reported in Item 11 is based on 18,856,611 American Depositary Shares (''ADS'') outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the Securities and Exchange Commission (the ''SEC'') on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares).</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Sphera Global Healthcare GP Ltd.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>900428</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>900428</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>900428</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>4.78</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>Percentage reported in Item 11 is based on 18,856,611 ADSs outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the SEC on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares).</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Sphera Global Healthcare Management LP.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>900428</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>900428</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>900428</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>4.78</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<comments>Percentage reported in Item 11 is based on 18,856,611 ADSs outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the SEC on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares).</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Chemomab Therapeutics Ltd.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>Kiryat Atidim, Building 7, Tel Aviv, Israel, 6158002</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Sphera Funds Management Ltd.&#13;
&#13;
Sphera Global Healthcare GP Ltd.&#13;
&#13;
Sphera Global Healthcare Management LP</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>Address of the Principal Business Office of each of the reporting persons is: 4 Itzhak Sade, Building A, 29th  Floor, Tel Aviv 6777504, Israel</principalBusinessOfficeOrResidenceAddress>
<citizenship>Each of the reporting person is organized under the laws of the State of Israel</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>Incorporated by reference to Item 9 of the cover page of each reporting person. &#13;
&#13;
The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows:&#13;
&#13;
(1)	900,428 ADSs, representing a total of 4.78% of the total ADSs outstanding, are held directly by Sphera Biotech Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company").&#13;
	&#13;
Each ADS represents 20 ordinary shares of the Issuer. Note that the CUSIP number provided herein applies to the ADSs of the Issuer. No CUSIP number exists for the underlying ordinary shares.&#13;
&#13;
The Management Company is managed, controlled and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd. &#13;
&#13;
This Statement shall not be construed as an admission by any of the reporting persons that it is the beneficial owner of any of the securities covered by this statement, and each reporting person disclaims beneficial ownership of any such securities. In addition, the reporting persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the reporting persons and other entities named in this Schedule 13G disclaims the existence of any such group.</amountBeneficiallyOwned>
<classPercent>Incorporated by reference to Item 11 of the cover page for each reporting person. &#13;
&#13;
Percentage reported in Item 11 for each reporting person is based on 18,856,611 ADSs outstanding as of December 31, 2024 (as reported in the Issuer's Annual Report on Form 20-F filed with the SEC on April 4, 2025, which provides that 377,132,220 ordinary shares, no par value, were outstanding as of December 31, 2024. Each ADS represents 20 ordinary shares).</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>See row 5 of cover page of each reporting person</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See row 6 of cover page of each reporting person and note in Item 4(a) above</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>See row 7 of cover page of each reporting person</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See row 8 of cover page of each reporting person and note in Item 4(a) above</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<exhibitInfo>Exhibit 1 Joint Filing Agreement by and among the Reporting Persons (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on August 20, 2024).&#13;
&#13;
https://www.sec.gov/Archives/edgar/data/1496201/000117891324002709/exhibit_1.htm</exhibitInfo>
<signatureInformation>
<reportingPersonName>Sphera Funds Management Ltd.</reportingPersonName>
<signatureDetails>
<signature>/s/ Adi Hanetz</signature>
<title>Adi Hanetz / General Counsel</title>
<date>04/10/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Sphera Global Healthcare GP Ltd.</reportingPersonName>
<signatureDetails>
<signature>/s/ Adi Hanetz</signature>
<title>Adi Hanetz / General Counsel</title>
<date>04/10/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Sphera Global Healthcare Management LP.</reportingPersonName>
<signatureDetails>
<signature>/s/ Adi Hanetz</signature>
<title>Adi Hanetz / General Counsel</title>
<date>04/10/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
